Hot Features
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne... Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.41 | 6.91854759568 | 20.38 | 22.89 | 20.25 | 2786347 | 21.08447701 | CS |
| 4 | 4.54 | 26.3188405797 | 17.25 | 22.89 | 16.56 | 2249236 | 19.53219897 | CS |
| 12 | 2.9 | 15.3520381154 | 18.89 | 22.89 | 15.87 | 1811692 | 18.89685596 | CS |
| 26 | 2.2 | 11.2302194997 | 19.59 | 22.89 | 14 | 2012897 | 18.06406249 | CS |
| 52 | 13.06 | 149.59908362 | 8.73 | 25 | 8.06 | 2460846 | 16.38383016 | CS |
| 156 | 10.7 | 96.4833183048 | 11.09 | 47.45 | 6.36 | 1784410 | 18.3326273 | CS |
| 260 | 0.75 | 3.56463878327 | 21.04 | 47.45 | 4.3 | 1179080 | 17.72975195 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.